biostudies-literatureUnknown21(7)Kim SHBukwang Pharmaceuticals<h4>Objective</h4>This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia.<h4>Methods</h4>Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed.<h4>Results</h4>Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -2Psychiatry investigation762-771https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298266biostudies-literatureEfficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial.PMC11298266Youn HKim EKim CELee JChoi JLee KYKim MLee JSKim SGLee BJJung SWChee HSKim SIKim SHWon SKim WHCheon EJKang NKim MHSong HROh HSLee HJKim DHPark JIKim HGLee SHRoh SPark DHPaik JWCho SJLee BOLee KUChang JGLee SYJung DUJung HYChung IWfalseEfficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial.<h4>Objective</h4>This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia.<h4>Methods</h4>Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed.<h4>Results</h4>Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -22024-01-01T00:00:00Z2024 Jul2025-04-18T22:38:43.143Z2025-02-19T04:41:04.047ZS-EPMC112982663908970210.30773/pi.2024.0052